Abound Wealth Management Decreases Position in Danaher Co. (NYSE:DHR)

Abound Wealth Management lowered its stake in shares of Danaher Co. (NYSE:DHR) by 32.7% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 224 shares of the conglomerate’s stock after selling 109 shares during the quarter. Abound Wealth Management’s holdings in Danaher were worth $56,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of DHR. Cape Investment Advisory Inc. purchased a new position in shares of Danaher during the fourth quarter worth about $25,000. Tsfg LLC lifted its stake in Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after buying an additional 88 shares during the last quarter. CarsonAllaria Wealth Management Ltd. acquired a new position in shares of Danaher in the 2nd quarter valued at $25,000. nVerses Capital LLC purchased a new position in shares of Danaher during the second quarter worth about $25,000. Finally, Redmont Wealth Advisors LLC acquired a new position in Danaher in the 1st quarter valued at about $30,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Activity

In related news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at $5,566,486.80. The disclosure for this sale can be found here. Insiders sold 39,659 shares of company stock valued at $11,042,433 in the last ninety days. Company insiders own 11.10% of the company’s stock.

Danaher Trading Up 0.6 %

Shares of DHR opened at $274.25 on Monday. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $281.70. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The firm has a 50 day simple moving average of $264.55 and a 200-day simple moving average of $256.51. The stock has a market cap of $198.07 billion, a price-to-earnings ratio of 46.48, a price-to-earnings-growth ratio of 4.48 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the prior year, the business earned $2.05 earnings per share. The business’s revenue was down 2.9% on a year-over-year basis. Equities analysts forecast that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.39%. The ex-dividend date is Friday, September 27th. Danaher’s payout ratio is 18.31%.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Barclays lifted their target price on Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 24th. The Goldman Sachs Group upped their price objective on shares of Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Bank of America lifted their price objective on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Finally, Stifel Nicolaus increased their target price on Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a research note on Wednesday, July 24th. Seven investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat, Danaher currently has an average rating of “Moderate Buy” and an average target price of $278.94.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.